On March 13 2026 the American College of Cardiology and American Heart Association released its 2026 Multisociety Guideline on the Management of Dyslipidemia, and on March 16 2026 Esperion Therapeutics announced that bempedoic acid had been added to the guideline as a Class 1 recommendation for patients with statin intolerance and for primary and secondary cardiovascular prevention.
The guideline places bempedoic acid on equal footing with PCSK9 monoclonal antibodies and ezetimibe as add‑on therapy after statins, underscoring its clinical value. The recommendation is supported by the CLEAR Outcomes study, which demonstrated a significant reduction in cardiovascular events among patients who could not tolerate statins and a similar benefit in primary‑prevention subgroups.
From a business perspective, the endorsement is expected to strengthen Esperion’s market position by facilitating pricing and reimbursement negotiations and by expanding the patient population eligible for the drug. The company anticipates that the guideline will translate into higher prescription volumes and, consequently, increased revenue growth in the United States and internationally.
Financially, Esperion reported a 144% year‑over‑year increase in total revenue to $168.4 million in Q4 2025, and a 21% rise to $403.1 million for the full year. U.S. net product revenue grew 38% YoY in Q4 to $43.7 million and reached $159.6 million for the year. Net income in Q4 was $61.8 million, but the company posted a $22.7 million net loss for 2025. Earnings per share in Q4 were $0.22, below analyst estimates of $0.23–$0.26. CEO Sheldon Koenig said, "The multiple Class 1 recommendations for bempedoic acid underscore its validation as a rigorously studied, evidence‑based therapy for patients who require additional LDL‑C lowering or who are unable to tolerate statins." He added that the recognition marks a "significant milestone for patients, clinicians and Esperion."
Strategically, Esperion has reduced its debt by $55 million and ended 2025 with $167.9 million in cash. The company is pursuing the acquisition of Corstasis Therapeutics to accelerate growth and expects to become cash‑generating in 2026. These moves position Esperion to capitalize on the guideline endorsement while strengthening its financial foundation.
The inclusion of bempedoic acid in the 2026 ACC/AHA Guideline is a material regulatory event that is likely to influence Esperion’s pricing strategy, reimbursement landscape, and long‑term revenue trajectory. The company’s recent financial performance, combined with its strategic initiatives, suggests that the guideline endorsement could serve as a catalyst for sustained growth and market expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.